Protagonist Therapeutics (PTGX) Retained Earnings (2017 - 2025)
Historic Retained Earnings for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$426.3 million.
- Protagonist Therapeutics' Retained Earnings rose 972.05% to -$426.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$426.3 million, marking a year-over-year increase of 972.05%. This contributed to the annual value of -$340.5 million for FY2024, which is 4469.44% up from last year.
- Per Protagonist Therapeutics' latest filing, its Retained Earnings stood at -$426.3 million for Q3 2025, which was up 972.05% from -$386.9 million recorded in Q2 2025.
- Over the past 5 years, Protagonist Therapeutics' Retained Earnings peaked at -$307.8 million during Q1 2021, and registered a low of -$643.0 million during Q3 2023.
- Over the past 5 years, Protagonist Therapeutics' median Retained Earnings value was -$430.3 million (recorded in 2022), while the average stood at -$454.4 million.
- As far as peak fluctuations go, Protagonist Therapeutics' Retained Earnings crashed by 4423.75% in 2021, and later skyrocketed by 4469.44% in 2024.
- Over the past 5 years, Protagonist Therapeutics' Retained Earnings (Quarter) stood at -$409.4 million in 2021, then tumbled by 31.12% to -$536.8 million in 2022, then fell by 14.71% to -$615.7 million in 2023, then surged by 44.69% to -$340.5 million in 2024, then fell by 25.19% to -$426.3 million in 2025.
- Its last three reported values are -$426.3 million in Q3 2025, -$386.9 million for Q2 2025, and -$352.2 million during Q1 2025.